

COMPLETE IF KNOWN

(use as many sheets as necessary)

Sheet

1

of

2

Application Number**Filing Date**

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number 21414

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
			EP 532 456		Ciba Geigy	12/08/1991
			WO 98 31677		Pierre Fabre	07/23/1998
			WO 97 45119		Novartis Ag	12/04/1997
			WO 98 05336		SmithKline Beecham Corporation	02/12/1998
			WO 94 21615		Merck Sharp & Dohme	09/29/1994
			DE 4241632		Dr. Karl Thomas GmbH	06/16/1994
			FR 2758328 (English language abstract)		Pierre Fabre	01/15/1997
			WO 99 51589		Hoechst Schering	03/23/1999
			WO 97 43279		Janssen	11/02/1997
			FR 2758327 (English language abstract)		Pierre Fabre	01/15/1997

Examiner
SignatureDate
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder). Merck & Co., Inc. 12/1/2007

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number		
			Filing Date		
			First Named Inventor		
			Group Art Unit		
			Examiner Name		
Sheet	2	of	2	Attorney Docket Number	21414

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Danysz, W., et al., Pharmacological Rev., Vol. 50, pp. 597-664, 1998
		Dickenson, A., TIPS, Vol. 11, pp. 307-309, 1990
		Wenzel, A., et al., Neurochemistry, Vol. 7, pp. 45-48, 1995
		Kew, J. N. C., et al., Brit. J. Pharmacology, Vol. 123, pp. 463-472, 1998
		Boyce, S., et al., Neuropharmacology, Vol. 38, pp. 611-623, 1999
		Laurie, D. J., et al., Mol. Brain Res., Vol. 51, pp. 23-32, 1997
		Ishii, T., et al., J. Biol. Chem, Vol. 268, pp. 2836-2843, 1993
		Max, M. B., et al., Clin. Neuropharmacology, Vol. 18, pp. 360-368, 1995
		Knox, D. J., et al., Anaesth. Intens. Care, Vol. 23, pp. 620-622, 1995
		Eide, P. K., et al., Pain, Vol. 61, pp. 221-228, 1995
		Kristensen, J. D., et al., Pain, Vol. 51, pp. 249-253, 1992
		Taniguchi, K, et al., Brit. J. Pharmacology, Vol. 122, pp. 809-812, 1997
		Isabelle Parrot, et al., Synthesis of Substituted 3-Amino-6-Arylpyridazines via Suzuki Reaction, Vol. 7, pp. 1163-1168, 1999
		J. Moragues, et al., Dopaminergic Activity in a Series of N-substituted 2-Aminopyrimides, Vol. 35, pp. 951-964, 1980

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 12/1/2007